Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette BPC 157: Prohibited peptide and unapproved drug in supplements